Go Pro
→ AI is not over (From The Oxford Club) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
BioLineRx Ltd. stock logo
BLRX
BioLineRx
$2.82
+4.4%		$3.13
$2.15
▼
$4.56
$12.32M1.5420,890 shs9,652 shs
Cocrystal Pharma, Inc. stock logo
COCP
Cocrystal Pharma
$0.82
-5.5%		$1.00
$0.76
▼
$2.67
$11.31M1.4327,642 shs34,120 shs
Phio Pharmaceuticals Corp. stock logo
PHIO
Phio Pharmaceuticals
$1.03
-0.5%		$1.05
$0.81
▼
$4.19
$11.91M0.821.55 million shs93,073 shs
Vaccinex, Inc. stock logo
VCNX
Vaccinex
$0.85
-28.3%		$1.05
$0.31
▼
$1.50
$2.76M1.13,275 shs103 shs
10 Stocks Powering The Next AI Boom Cover
10 Stocks Powering The Next AI Boom

The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation.

Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
BioLineRx Ltd. stock logo
BLRX
BioLineRx
0.00%0.00%-14.29%-1.40%-29.68%
Cocrystal Pharma, Inc. stock logo
COCP
Cocrystal Pharma
0.00%-8.90%-21.15%-40.58%-50.90%
Phio Pharmaceuticals Corp. stock logo
PHIO
Phio Pharmaceuticals
0.00%-1.44%+2.50%-10.09%-57.82%
Vaccinex, Inc. stock logo
VCNX
Vaccinex
0.00%-28.33%-17.09%-15.43%+5.71%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
BioLineRx Ltd. stock logo
BLRX
BioLineRx
$2.82
+4.4%		$3.13
$2.15
▼
$4.56
$12.32M1.5420,890 shs9,652 shs
Cocrystal Pharma, Inc. stock logo
COCP
Cocrystal Pharma
$0.82
-5.5%		$1.00
$0.76
▼
$2.67
$11.31M1.4327,642 shs34,120 shs
Phio Pharmaceuticals Corp. stock logo
PHIO
Phio Pharmaceuticals
$1.03
-0.5%		$1.05
$0.81
▼
$4.19
$11.91M0.821.55 million shs93,073 shs
Vaccinex, Inc. stock logo
VCNX
Vaccinex
$0.85
-28.3%		$1.05
$0.31
▼
$1.50
$2.76M1.13,275 shs103 shs
10 Stocks Powering The Next AI Boom Cover
10 Stocks Powering The Next AI Boom

The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation.

Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
BioLineRx Ltd. stock logo
BLRX
BioLineRx
0.00%0.00%-14.29%-1.40%-29.68%
Cocrystal Pharma, Inc. stock logo
COCP
Cocrystal Pharma
0.00%-8.90%-21.15%-40.58%-50.90%
Phio Pharmaceuticals Corp. stock logo
PHIO
Phio Pharmaceuticals
0.00%-1.44%+2.50%-10.09%-57.82%
Vaccinex, Inc. stock logo
VCNX
Vaccinex
0.00%-28.33%-17.09%-15.43%+5.71%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
BioLineRx Ltd. stock logo
BLRX
BioLineRx
1.00
SellN/AN/A
Cocrystal Pharma, Inc. stock logo
COCP
Cocrystal Pharma
1.00
SellN/AN/A
Phio Pharmaceuticals Corp. stock logo
PHIO
Phio Pharmaceuticals
2.00
Hold$14.001,265.85% Upside
Vaccinex, Inc. stock logo
VCNX
Vaccinex
0.00
N/AN/AN/A

Current Analyst Ratings Breakdown

Latest VCNX, COCP, PHIO, and BLRX Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
7/17/2026
BioLineRx Ltd. stock logo
BLRX
BioLineRx
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (E+)
7/17/2026
Phio Pharmaceuticals Corp. stock logo
PHIO
Phio Pharmaceuticals
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (E+)
6/8/2026
Cocrystal Pharma, Inc. stock logo
COCP
Cocrystal Pharma
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeSell (E+) ➝ Sell (D-)
5/22/2026
Cocrystal Pharma, Inc. stock logo
COCP
Cocrystal Pharma
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeSell (D-) ➝ Sell (E+)
(Data available from 8/2/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
BioLineRx Ltd. stock logo
BLRX
BioLineRx
$1.18M10.44N/AN/A$5.36 per share0.53
Cocrystal Pharma, Inc. stock logo
COCP
Cocrystal Pharma
N/AN/AN/AN/A$0.46 per shareN/A
Phio Pharmaceuticals Corp. stock logo
PHIO
Phio Pharmaceuticals
N/AN/AN/AN/A$1.87 per shareN/A
Vaccinex, Inc. stock logo
VCNX
Vaccinex
$388K5.67N/AN/A($2.59) per share-0.33
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
BioLineRx Ltd. stock logo
BLRX
BioLineRx
-$1.17M-$1.92N/AN/AN/A-563.70%-37.73%-19.42%8/13/2026 (Estimated)
Cocrystal Pharma, Inc. stock logo
COCP
Cocrystal Pharma
-$8.83M-$0.73N/AN/AN/AN/A-150.61%-97.86%8/13/2026 (Estimated)
Phio Pharmaceuticals Corp. stock logo
PHIO
Phio Pharmaceuticals
-$8.70M-$1.38N/AN/AN/AN/A-77.34%-70.87%8/13/2026 (Estimated)
Vaccinex, Inc. stock logo
VCNX
Vaccinex
-$20.25M-$48.27N/AN/AN/AN/AN/A-383.58%8/10/2026 (Estimated)

Latest VCNX, COCP, PHIO, and BLRX Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/13/2026Q2 2026
BioLineRx Ltd. stock logo
BLRX
BioLineRx
-$0.15N/AN/AN/A$0.43 millionN/A
8/13/2026N/A
Cocrystal Pharma, Inc. stock logo
COCP
Cocrystal Pharma
-$0.17N/AN/AN/A$0.23 millionN/A
8/13/2026Q2 2026
Phio Pharmaceuticals Corp. stock logo
PHIO
Phio Pharmaceuticals
-$0.36N/AN/AN/AN/AN/A
8/10/2026N/A
Vaccinex, Inc. stock logo
VCNX
Vaccinex
-$73.0380N/AN/AN/A$0.05 millionN/A
5/27/2026Q1 2026
BioLineRx Ltd. stock logo
BLRX
BioLineRx
-$1.04-$0.36+$0.68N/A$0.34 million$0.48 million
5/15/2026Q1 2026
Cocrystal Pharma, Inc. stock logo
COCP
Cocrystal Pharma
-$0.15-$0.17-$0.02-$0.17$0.23 million$0.23 million
5/7/2026Q1 2026
Phio Pharmaceuticals Corp. stock logo
PHIO
Phio Pharmaceuticals
-$0.24-$0.34-$0.10-$0.34N/AN/A
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
BioLineRx Ltd. stock logo
BLRX
BioLineRx
N/AN/AN/AN/AN/A
Cocrystal Pharma, Inc. stock logo
COCP
Cocrystal Pharma
N/AN/AN/AN/AN/A
Phio Pharmaceuticals Corp. stock logo
PHIO
Phio Pharmaceuticals
N/AN/AN/AN/AN/A
Vaccinex, Inc. stock logo
VCNX
Vaccinex
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
BioLineRx Ltd. stock logo
BLRX
BioLineRx
0.16
1.58
1.43
Cocrystal Pharma, Inc. stock logo
COCP
Cocrystal Pharma
N/A
2.66
2.66
Phio Pharmaceuticals Corp. stock logo
PHIO
Phio Pharmaceuticals
N/A
18.32
18.32
Vaccinex, Inc. stock logo
VCNX
Vaccinex
N/A
0.77
0.77

Institutional Ownership

CompanyInstitutional Ownership
BioLineRx Ltd. stock logo
BLRX
BioLineRx
1.56%
Cocrystal Pharma, Inc. stock logo
COCP
Cocrystal Pharma
6.72%
Phio Pharmaceuticals Corp. stock logo
PHIO
Phio Pharmaceuticals
57.31%
Vaccinex, Inc. stock logo
VCNX
Vaccinex
50.11%

Insider Ownership

CompanyInsider Ownership
BioLineRx Ltd. stock logo
BLRX
BioLineRx
1.10%
Cocrystal Pharma, Inc. stock logo
COCP
Cocrystal Pharma
39.40%
Phio Pharmaceuticals Corp. stock logo
PHIO
Phio Pharmaceuticals
0.89%
Vaccinex, Inc. stock logo
VCNX
Vaccinex
51.50%
CompanyEmployeesShares OutstandingFree FloatOptionable
BioLineRx Ltd. stock logo
BLRX
BioLineRx
404.37 million4.32 millionOptionable
Cocrystal Pharma, Inc. stock logo
COCP
Cocrystal Pharma
1013.79 million8.36 millionNot Optionable
Phio Pharmaceuticals Corp. stock logo
PHIO
Phio Pharmaceuticals
1011.62 million11.51 millionNot Optionable
Vaccinex, Inc. stock logo
VCNX
Vaccinex
402.60 million1.26 millionNo Data

Recent News About These Companies

Vaccinex to Report New Biomarker Data and Plans for Phase 2B Clinical Trial of Pepinemab in AD at the Alzheimer's Association International Conference in London on July 13, 2026
July 8, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/07/08/3324070/34858/en/vaccinex-to-report-new-biomarker-data-and-plans-for-phase-2b-clinical-trial-of-pepinemab-in-ad-at-the-alzheimer-s-association-international-conference-in-london-on-july-13-2026.html
Vaccinex, Inc. Reports Financial Results for Year Ended December 31, 2025
April 29, 2026  |  quiverquant.comQ
Vaccinex Reports 2025 Annual Financial Results
April 29, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/04/30/3284388/34858/en/vaccinex-reports-2025-annual-financial-results.html
Vaccinex Inc.
April 10, 2026  |  barrons.comhttps://www.barrons.com/market-data/stocks/vcnx/company-people
Vaccinex announces $60M revenue sharing agreement with PDV
December 23, 2025  |  msn.comhttps://www.msn.com/en-us/money/other/vaccinex-announces-60m-revenue-sharing-agreement-with-pdv/ar-AA1SUmDZ
Vaccinex, Inc. Announces $60 million Agreement to Finance a Phase 2b clinical trial of pepinemab to treat Alzheimer’s Disease
December 23, 2025  |  markets.businessinsider.comhttps://markets.businessinsider.com/news/stocks/vaccinex-inc-announces-60-million-agreement-to-finance-a-phase-2b-clinical-trial-of-pepinemab-to-treat-alzheimer-s-disease-1035667359
Vaccinex, Inc. Engages in $60 Million Revenue Sharing Agreement with Pepinemab Development Venture to Advance Alzheimer’s Treatment
December 23, 2025  |  quiverquant.comQ
Vaccinex presents promising cancer treatment data at ASCO
May 29, 2025  |  uk.investing.comhttps://uk.investing.com/news/company-news/vaccinex-presents-promising-cancer-treatment-data-at-asco-93CH-4104876
Vaccinex, Inc. to Present New Data on Pepinemab's Role in Enhancing Immune Responses in Head and Neck Cancer at ASCO 2025
May 29, 2025  |  nasdaq.comhttps://www.nasdaq.com/articles/vaccinex-inc-present-new-data-pepinemabs-role-enhancing-immune-responses-head-and-neck
Vaccinex to Report Promising New Clinical Results of Neoadjuvant Treatment with Pepinemab to Enhance Immunotherapy in Patients with Head and Neck Cancer at ASCO Annual Meeting
May 27, 2025  |  globenewswire.comhttps://www.globenewswire.com/news-release/2025/05/27/3088645/34858/en/vaccinex-to-report-promising-new-clinical-results-of-neoadjuvant-treatment-with-pepinemab-to-enhance-immunotherapy-in-patients-with-head-and-neck-cancer-at-asco-annual-meeting.html
AbTherx, Inc: AbTherx, Single Cell Technology, and Vaccinex Announce Collaboration to Tackle Challenging Antibody Drug Targets
May 13, 2025  |  finanznachrichten.dehttps://www.finanznachrichten.de/nachrichten-2025-05/65384714-abtherx-inc-abtherx-single-cell-technology-and-vaccinex-announce-collaboration-to-tackle-challenging-antibody-drug-targets-200.htm
AbTherx, Single Cell Technology, and Vaccinex Announce Collaboration to Tackle Challenging Antibody Drug Targets
May 13, 2025  |  finance.yahoo.comhttps://finance.yahoo.com/news/abtherx-single-cell-technology-vaccinex-100000437.html
Vaccinex to report new clinical data on pepinemab in enhancing immunotherapy
April 22, 2025  |  markets.businessinsider.comhttps://markets.businessinsider.com/news/stocks/vaccinex-to-report-new-clinical-data-on-pepinemab-in-enhancing-immunotherapy-1034603197
Vaccinex, Inc. Announces Promising Data on Pepinemab as Neoadjuvant Immunotherapy in Metastatic Melanoma and Head and Neck Cancer at AACR 2025
April 21, 2025  |  quiverquant.comQ
Vaccinex to Report Promising New Clinical Data Revealing Pepinemab's Unique Mechanism to Enhance Immunotherapy at Annual Meeting of American Association for Cancer Research (AACR)
April 21, 2025  |  globenewswire.comhttps://www.globenewswire.com/news-release/2025/04/21/3064665/34858/en/vaccinex-to-report-promising-new-clinical-data-revealing-pepinemab-s-unique-mechanism-to-enhance-immunotherapy-at-annual-meeting-of-american-association-for-cancer-research-aacr.html
Vaccinex director resigns, no disagreement cited
March 21, 2025  |  investing.comhttps://www.investing.com/news/sec-filings/vaccinex-director-resigns-no-disagreement-cited-93CH-3937856
Vaccinex plans Nasdaq exit as Alzheimer market pressure grows
March 10, 2025  |  finance.yahoo.comhttps://finance.yahoo.com/news/vaccinex-plans-nasdaq-exit-alzheimer-211545558.html
Vaccinex, Inc.: Vaccinex Plans to Delist its Common Stock from The Nasdaq Stock Market
March 8, 2025  |  finanznachrichten.dehttps://www.finanznachrichten.de/nachrichten-2025-03/64767350-vaccinex-inc-vaccinex-plans-to-delist-its-common-stock-from-the-nasdaq-stock-market-399.htm
Vaccinex to delist common stock from Nasdaq
March 7, 2025  |  markets.businessinsider.comhttps://markets.businessinsider.com/news/stocks/vaccinex-to-delist-common-stock-from-nasdaq-1034455385
Vaccinex Plans to Delist its Common Stock from The Nasdaq Stock Market
March 7, 2025  |  globenewswire.comhttps://www.globenewswire.com/news-release/2025/03/07/3039274/34858/en/vaccinex-plans-to-delist-its-common-stock-from-the-nasdaq-stock-market.html

New MarketBeat Followers Over Time

Media Sentiment Over Time

BioLineRx stock logo

BioLineRx NASDAQ:BLRX

$2.82 +0.12 (+4.44%)
Closing price 07/31/2026 03:59 PM Eastern
Extended Trading
$2.86 +0.04 (+1.42%)
As of 07/31/2026 07:34 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

BioLineRx Ltd., a commercial stage biopharmaceutical company, develops and commercializes therapeutics for oncology and rare diseases. The company's pipeline includes APHEXDA (motixafortide), a peptide that is in Phase 1 clinical trial for the treatment of sickle cell disease, and Phase 2b clinical trial for the treatment of pancreatic cancer, as well as completed Phase 3 clinical trial for the treatment of multiple myeloma. It also develops BL-5010, a pen-like applicator containing an acidic aqueous solution for the non-surgical removal of skin lesions. BioLineRx Ltd. was incorporated in 2003 and is headquartered in Hevel Modi'in, Israel.

Cocrystal Pharma stock logo

Cocrystal Pharma NASDAQ:COCP

$0.82 -0.05 (-5.50%)
Closing price 07/31/2026 04:00 PM Eastern
Extended Trading
$0.86 +0.04 (+4.39%)
As of 07/31/2026 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Cocrystal Pharma, Inc., a biotechnology company, focuses on the discovery and development of antiviral therapeutic treatments for serious and/or chronic viral diseases. It employs structure-based technologies to create antiviral drugs primarily to treat hepatitis C virus (HCV), influenza virus, coronavirus, norovirus, and respiratory virus infections. The company develops CC-31244, a HCV non-nucleoside polymerase inhibitor that has completed Phase II a clinical trial to treat HCV infection; and CC-42344, a PB2 inhibitor that has completed Phase I clinical trial for treating influenza infection. It is also involved in identifying and developing non-nucleoside polymerase inhibitors for norovirus infections. Cocrystal Pharma, Inc. has a license and research collaboration agreement with Merck Sharp & Dohme Corp. to discover and develop proprietary influenza A/B antiviral agents; and a license agreement with Kansas State University Research Foundation to develop antiviral compounds for the treatment of norovirus and coronavirus infections. The company is headquartered in Bothell, Washington.

Phio Pharmaceuticals stock logo

Phio Pharmaceuticals NASDAQ:PHIO

$1.02 -0.01 (-0.49%)
Closing price 07/31/2026 04:00 PM Eastern
Extended Trading
$0.99 -0.04 (-3.51%)
As of 07/31/2026 07:46 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Phio Pharmaceuticals Corp. engages in the development of immuno-oncology therapeutics in the United States. The company is developing PH-762, an INTASYL compound in Phase 1b dose-escalating clinical trials to reduce the expression of cell death protein 1 (PD-1), a protein that inhibits T cells' ability to kill cancer cells; and PH-762 treated double positive tumor infiltrating lymphocytes, which is in Phase 1 clinical trials to treat advanced melanoma and other advanced solid tumors. It is also developing PH-894, an INTASYL compound in IND enabling studies to silence BRD4, a protein that controls gene expression in both T cells and tumor cells, effecting the immune system and the tumor. The company was formerly known as RXi Pharmaceuticals Corporation and changed its name to Phio Pharmaceuticals Corp. in November 2018. Phio Pharmaceuticals Corp. was incorporated in 2011 and is based in Marlborough, Massachusetts.

Vaccinex stock logo

Vaccinex NASDAQ:VCNX

$0.85 -0.33 (-28.33%)
As of 07/31/2026 09:49 AM Eastern

Vaccinex, Inc., a clinical-stage biotechnology company, engages in the discovery and development of targeted biotherapeutics to treat cancer, neurodegenerative diseases, and autoimmune disorders. The company's lead drug candidate, pepinemab, a humanized monoclonal antibody that binds and blocks the activity of SEMA4D. It is developing Pepinemab, which is in phase 2 study for treatment of Alzheimer's disease and has completed phase 2 study for treatment of Huntington's disease; Pepinemab in combination with Pembrolizumab in phase 2 study for head and neck cancer, Avelumab in phase 2 study for pancreatic cancer, and completed phase 2 study with Avelumab for non-small cell lung cancer; and Pepinemab in combination with Nivolumab completed phase 2 study for melanoma, and trastuzumab and DC vaccine in phase 2 study for breast cancer. The company has also developed ActivMAb, an antibody drug discovery platform based on a novel method for complex targets, such as multi-pass membrane receptors or large and diverse libraries of full-length human monoclonal antibodies on the surface of pox viruses. It has collaborations with Merck Sharp & Dohme; Ares Trading S.A.; The Children's Hospital of Philadelphia; Emory University; Huntington Study Group; H. Lee Moffitt Cancer Center and Research Institute, Inc; Catalent Pharma Solutions, LLC; Surface Oncology, Inc.; and Pharmaceutical and Biotech Co. The company was incorporated in 2001 and is headquartered in Rochester, New York.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas